TY - JOUR
T1 - Comparison of best versus worst clinical outcomes for adult spinal deformity surgery
T2 - A retrospective review of a prospectively collected, multicenter database with 2-year follow-up
AU - International Spine Study Group
AU - Smith, Justin S.
AU - Shaffrey, Christopher I.
AU - Lafage, Virginie
AU - Schwab, Frank
AU - Scheer, Justin K.
AU - Protopsaltis, Themistocles
AU - Klineberg, Eric
AU - Gupta, Munish
AU - Hostin, Richard
AU - Fu, Kai Ming G.
AU - Mundis, Gregory M.
AU - Kim, Han Jo
AU - Deviren, Vedat
AU - Soroceanu, Alex
AU - Hart, Robert A.
AU - Burton, Douglas C.
AU - Bess, Shay
AU - Ames, Christopher P.
N1 - Funding Information:
The ISSG is funded through research grants from DePuy Synthes and individual donations. Dr. Smith reports being a consultant for Biomet, NuVasive, Cerapedics, Medtronic, and DePuy; receiving clinical or research support from DePuy/ISSG Foundation (ISSGF) for the study described; and receiving support from DePuy/ ISSGF for non-study-related clinical or research effort. Dr. Shaffrey reports being a consultant for Biomet, Globus, Medtronic, NuVasive, and Stryker and holding patents with and receiving royalties from Biomet, Medtronic, and NuVasive. Dr. Lafage reports being a consultant for MSD; direct stock ownership in Nemaris, Inc.; receiving support from DePuy, SRS, ISSGF, and NIH for non-study-related clinical or research effort; and being a speaker/teacher for DePuy, K2M, NuVasive, and Nemaris, Inc. Dr. Schwab reports being a consultant for MSD, K2M, DePuy, and Medicrea; direct stock ownership in Nemaris, Inc.; holding patents with MSD, Nemaris, K2M, and NuVasive; receiving support from DePuy, MSD, and AO for non-study-related clinical or research effort; and being a speaker/teacher for MSD, Nemaris, Inc., and K2M. Dr. Protopsaltis reports being a consultant for Medicrea and Biomet Spine and receiving support from Zimmer Spine for non-study-related clinical or research effort. Dr. Klineberg reports receiving speaker fees and/or a fellowship grant from DePuy Synthes, AO Spine, and OREF. Dr. Gupta reports direct stock ownership in Johnson & Johnson, Proctor & Gamble, Pfizer, and Pioneer; being a consultant for DePuy Synthes, Medtronic, and Medicrea; receiving royalties from DePuy Synthes; and being a board member and/or treasurer of SRS and FOSA. Dr. Hostin reports being a consultant for DePuy and receiving support from NuVasive, Seeger, DJO, DePuy, and K2M for non-study-related clinical or research effort. Dr. Fu reports being a consultant for Medtronic and DePuy. Dr. Mundis reports being a consultant for NuVasive and K2M; receiving support from NuVasive for non-study-related clinical or research effort; and receiving royalties from NuVasive and K2M. Dr.Kim reports being a consultant for, member of speaker bureau of, and/ or receiving traveling expense fees from DePuy, Stryker, Biomnet, K2M, and Medtronic. Dr. Deviren reports being a consultant for NuVasive, Guidepoint, and Stryker and reports UCSF received fellowship grant support from AO Spine, Globus, and NuVasive. Dr. Hart reports being a consultant for DePuy Synthes, Globus, and Medtronic; direct stock ownership in Spine Connect; holding a patent with OHSU; receiving support from Medtronic and ISSGF for non-study-related clinical or research effort; and receiving royalties and/or speaker bureau/paid honoraria from Seaspine and DePuy Synthes. Dr. Burton reports being a consultant for and holding a patent with DePuy Spine and receiving clinical or research support from DePuy Spine for the study described. Dr. Bess reports being a consultant for K2M and Allosource; receiving clinical or research support from DePuy Synthes for the study described; and receiving support from Medtronic and K2M for non-study-related clinical or research effort. Dr. Ames reports being a consultant for DePuy, Medtronic, and Stryker; direct stock ownership in Doctors Research Group and Biomet Spine; holding a patent with Fish & Richardson, P.C.; and receiving royalties from Aesculap and Baxano Surgery.
Publisher Copyright:
©AANS, 2015.
PY - 2015/9
Y1 - 2015/9
N2 - OBJECT: Although recent studies suggest that average clinical outcomes are improved following surgery for selected adult spinal deformity (ASD) patients, these outcomes span a broad range. Few studies have specifically addressed factors that may predict favorable clinical outcomes. The objective of this study was to compare patients with ASD with best versus worst clinical outcomes following surgical treatment to identify distinguishing factors that may prove useful for patient counseling and optimization of clinical outcomes. METHODS: This is a retrospective review of a prospectively collected, multicenter, database of consecutively enrolled patients with ASD who were treated operatively. Inclusion criteria were age > 18 years and ASD. For patients with a minimum of 2-year follow-up, those with best versus worst outcomes were compared separately based on Scoliosis Research Society-22 (SRS-22) and Oswestry Disability Index (ODI) scores. Only patients with a baseline SRS-22 ≤ 3.5 or ODI ≥ 30 were included to minimize ceiling/floor effects. Best and worst outcomes were defined for SRS-22 (≥ 4.5 and ≤ 2.5, respectively) and ODI (≤ 15 and ≥ 50, respectively). RESULTS: Of 257 patients who met the inclusion criteria, 227 (88%) had complete baseline and 2-year follow-up SRS-22 and ODI outcomes scores and radiographic imaging and were analyzed in the present study. Of these 227 patients, 187 had baseline SRS-22 scores ≤ 3.5, and 162 had baseline ODI scores ≥ 30. For the SRS-22, best and worst outcomes criteria were met at follow-up for 25 and 27 patients, respectively. For the ODI, best and worst outcomes criteria were met at follow-up for 43 and 51 patients, respectively. With respect to the SRS-22, compared with best outcome patients, those with worst outcomes had higher baseline SRS-22 scores (p < 0.0001), higher prevalence of baseline depression (p < 0.001), more comorbidities (p = 0.012), greater prevalence of prior surgery (p = 0.007), a higher complication rate (p = 0.012), and worse baseline deformity (sagittal vertical axis [SVA], p = 0.045; pelvic incidence [PI] and lumbar lordosis [LL] mismatch, p = 0.034). The best-fit multivariate model for SRS-22 included baseline SRS-22 (p = 0.033), baseline depression (p = 0.012), and complications (p = 0.030). With respect to the ODI, compared with best outcome patients, those with worst outcomes had greater baseline ODI scores (p < 0.001), greater baseline body mass index (BMI; p = 0.002), higher prevalence of baseline depression (p < 0.028), greater baseline SVA (p = 0.016), a higher complication rate (p = 0.02), and greater 2-year SVA (p < 0.001) and PI-LL mismatch (p = 0.042). The best-fit multivariate model for ODI included baseline ODI score (p < 0.001), 2-year SVA (p = 0.014) and baseline BMI (p = 0.037). Age did not distinguish best versus worst outcomes for SRS-22 or ODI (p > 0.1). CONCLUSIONS: Few studies have specifically addressed factors that distinguish between the best versus worst clinical outcomes for ASD surgery. In this study, baseline and perioperative factors distinguishing between the best and worst outcomes for ASD surgery included several patient factors (baseline depression, BMI, comorbidities, and disability), as well as residual deformity (SVA), and occurrence of complications. These findings suggest factors that may warrant greater awareness among clinicians to achieve optimal surgical outcomes for patients with ASD.
AB - OBJECT: Although recent studies suggest that average clinical outcomes are improved following surgery for selected adult spinal deformity (ASD) patients, these outcomes span a broad range. Few studies have specifically addressed factors that may predict favorable clinical outcomes. The objective of this study was to compare patients with ASD with best versus worst clinical outcomes following surgical treatment to identify distinguishing factors that may prove useful for patient counseling and optimization of clinical outcomes. METHODS: This is a retrospective review of a prospectively collected, multicenter, database of consecutively enrolled patients with ASD who were treated operatively. Inclusion criteria were age > 18 years and ASD. For patients with a minimum of 2-year follow-up, those with best versus worst outcomes were compared separately based on Scoliosis Research Society-22 (SRS-22) and Oswestry Disability Index (ODI) scores. Only patients with a baseline SRS-22 ≤ 3.5 or ODI ≥ 30 were included to minimize ceiling/floor effects. Best and worst outcomes were defined for SRS-22 (≥ 4.5 and ≤ 2.5, respectively) and ODI (≤ 15 and ≥ 50, respectively). RESULTS: Of 257 patients who met the inclusion criteria, 227 (88%) had complete baseline and 2-year follow-up SRS-22 and ODI outcomes scores and radiographic imaging and were analyzed in the present study. Of these 227 patients, 187 had baseline SRS-22 scores ≤ 3.5, and 162 had baseline ODI scores ≥ 30. For the SRS-22, best and worst outcomes criteria were met at follow-up for 25 and 27 patients, respectively. For the ODI, best and worst outcomes criteria were met at follow-up for 43 and 51 patients, respectively. With respect to the SRS-22, compared with best outcome patients, those with worst outcomes had higher baseline SRS-22 scores (p < 0.0001), higher prevalence of baseline depression (p < 0.001), more comorbidities (p = 0.012), greater prevalence of prior surgery (p = 0.007), a higher complication rate (p = 0.012), and worse baseline deformity (sagittal vertical axis [SVA], p = 0.045; pelvic incidence [PI] and lumbar lordosis [LL] mismatch, p = 0.034). The best-fit multivariate model for SRS-22 included baseline SRS-22 (p = 0.033), baseline depression (p = 0.012), and complications (p = 0.030). With respect to the ODI, compared with best outcome patients, those with worst outcomes had greater baseline ODI scores (p < 0.001), greater baseline body mass index (BMI; p = 0.002), higher prevalence of baseline depression (p < 0.028), greater baseline SVA (p = 0.016), a higher complication rate (p = 0.02), and greater 2-year SVA (p < 0.001) and PI-LL mismatch (p = 0.042). The best-fit multivariate model for ODI included baseline ODI score (p < 0.001), 2-year SVA (p = 0.014) and baseline BMI (p = 0.037). Age did not distinguish best versus worst outcomes for SRS-22 or ODI (p > 0.1). CONCLUSIONS: Few studies have specifically addressed factors that distinguish between the best versus worst clinical outcomes for ASD surgery. In this study, baseline and perioperative factors distinguishing between the best and worst outcomes for ASD surgery included several patient factors (baseline depression, BMI, comorbidities, and disability), as well as residual deformity (SVA), and occurrence of complications. These findings suggest factors that may warrant greater awareness among clinicians to achieve optimal surgical outcomes for patients with ASD.
KW - Adult spinal deformity
KW - Complications
KW - Depression
KW - Outcomes
KW - Pelvic parameters
KW - Sagittal alignment
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=84952720163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952720163&partnerID=8YFLogxK
U2 - 10.3171/2014.12.SPINE14777
DO - 10.3171/2014.12.SPINE14777
M3 - Review article
C2 - 26047345
AN - SCOPUS:84952720163
SN - 1547-5654
VL - 23
SP - 349
EP - 359
JO - Journal of neurosurgery. Spine
JF - Journal of neurosurgery. Spine
IS - 3
ER -